|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
131,000,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
462,585 |
462,585 |
462,585 |
462,585 |
Total Buy Value |
$5,865,243 |
$5,865,243 |
$5,865,243 |
$5,865,243 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
2 |
2 |
2 |
2 |
Total Shares Sold |
205,742 |
673,529 |
1,229,394 |
1,328,805 |
Total Sell Value |
$2,889,744 |
$10,854,607 |
$19,679,862 |
$20,587,033 |
Total People Sold |
4 |
6 |
6 |
8 |
Total Sell Transactions |
11 |
29 |
50 |
54 |
End Date |
2025-03-02 |
2024-11-29 |
2024-05-31 |
2023-06-01 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Weinhoff Gregory M |
Chief Business Officer |
|
2025-05-27 |
4 |
AS |
$12.82 |
$128,225 |
D/D |
(10,000) |
122,279 |
|
- |
|
Weinhoff Gregory M |
Chief Business Officer |
|
2025-05-27 |
4 |
OE |
$3.85 |
$38,500 |
D/D |
10,000 |
132,279 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2025-05-20 |
4 |
AS |
$12.71 |
$699,111 |
D/D |
(55,000) |
221,017 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2025-05-20 |
4 |
OE |
$3.85 |
$211,750 |
D/D |
55,000 |
276,017 |
|
- |
|
Goyal Arjun |
Director |
|
2025-05-16 |
4 |
B |
$12.73 |
$5,315,005 |
I/I |
417,646 |
462,585 |
2.1 |
- |
|
Goyal Arjun |
Director |
|
2025-05-15 |
4 |
B |
$12.24 |
$550,238 |
I/I |
44,939 |
44,939 |
2.1 |
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-05-01 |
4 |
AS |
$14.00 |
$4,354 |
D/D |
(311) |
105,386 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-05-01 |
4 |
OE |
$5.84 |
$1,816 |
D/D |
311 |
105,697 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-04-28 |
4 |
AS |
$14.01 |
$29,132 |
D/D |
(2,080) |
105,386 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-04-28 |
4 |
OE |
$5.84 |
$12,147 |
D/D |
2,080 |
107,466 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-04-25 |
4 |
AS |
$14.00 |
$50,526 |
D/D |
(3,609) |
105,386 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-04-25 |
4 |
OE |
$5.84 |
$21,077 |
D/D |
3,609 |
108,995 |
|
- |
|
Weinhoff Gregory M |
Chief Business Officer |
|
2025-04-25 |
4 |
AS |
$13.61 |
$159,857 |
D/D |
(11,742) |
122,279 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2025-04-22 |
4 |
AS |
$12.43 |
$501,476 |
D/D |
(40,344) |
221,017 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2025-04-21 |
4 |
AS |
$12.29 |
$180,100 |
D/D |
(14,656) |
261,361 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2025-03-20 |
4 |
AS |
$16.69 |
$918,060 |
D/D |
(55,000) |
276,017 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-03-17 |
4 |
AS |
$16.45 |
$98,697 |
D/D |
(6,000) |
105,386 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-03-17 |
4 |
OE |
$5.84 |
$35,040 |
D/D |
6,000 |
111,386 |
|
- |
|
Chao David M |
Chief Administrative Officer |
|
2025-03-17 |
4 |
AS |
$17.08 |
$120,206 |
D/D |
(7,000) |
225,007 |
|
- |
|
Chao David M |
Chief Administrative Officer |
|
2025-03-17 |
4 |
OE |
$3.85 |
$13,475 |
D/D |
3,500 |
232,007 |
|
- |
|
Weinhoff Gregory M |
Chief Business Officer |
|
2025-02-25 |
4 |
AS |
$15.25 |
$175,270 |
D/D |
(11,494) |
134,021 |
|
- |
|
Saha Saurabh |
Chief Executive Officer |
|
2025-02-20 |
4 |
AS |
$15.92 |
$876,088 |
D/D |
(55,000) |
331,017 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-02-18 |
4 |
AS |
$15.91 |
$97,065 |
D/D |
(6,000) |
105,386 |
|
- |
|
Hussain Iqbal J |
General Counsel |
|
2025-02-18 |
4 |
OE |
$5.84 |
$35,040 |
D/D |
6,000 |
111,386 |
|
- |
|
Anderson Karen M. |
Chief People Officer |
|
2025-02-10 |
4 |
AS |
$18.99 |
$8,147 |
D/D |
(429) |
54,322 |
|
- |
|
245 Records found
|
|
Page 1 of 10 |
|
|